Clinical-stage radiopharmaceutical companyAdvanCell, which is developing targeted therapies for cancer, appointed Sean Cassidy as chief financial officer (CFO). Cassidy joins the company as AdvanCell advances its clinical pipeline toward commercialization, bringing more than 20 years of industry leadership experience in both private and public life sciences companies.
Most recently, he served as CFO and treasurer of Arvinas, where he led multiple private and public financings, raising approximately $1.3 billion in private and public capital, as well as approximately $1 billion in non-dilutive capital through strategic partnerships with global pharmaceutical companies including Pfizer, Bayer, Genentech (now Roche), and Merck.
Cassidy also worked at Axerion Therapeutics, CuraGen, and 454 Life Sciences. He began his career at Deloitte & Touche and holds an MBA and BS in accounting from the University of Connecticut and is a certified public accountant (CPA).
Alto Neuroscience, a clinical-stage biopharmaceutical company developing medicines for neuropsychiatric disorders, has promoted Nick Smith to president and CFO. Smith joined Alto in 2021 as chief business officer and has served as chief financial officer since 2022. During his tenure, he has led Alto’s corporate development and capital strategy, including the company’s initial public offering, the acquisition of ALTO-207 in May 2025, and subsequent financings supporting the program’s development.
He will continue to lead Alto’s finance function and oversee corporate strategy and business development. Smith has held roles of increasing responsibility at Aptinyx, as well as Kastle Therapeutics and Lundbeck. He holds a BA in accounting and finance from North Central College.
Alterome Therapeutics, a clinical-stage biopharmaceutical targeting oncogenic driver mutations for the treatment of cancer, announced Johanna Mylet, CPA, as its CFO. Mylet comes from Poseida Therapeutics where she held roles of increasingresponsibility, culminating to CFO until it was acquired by Roche in 2025.
She previously served as controller at Huya Bioscience International and as an audit manager at Grant Thornton LLP. Mylet holds a Bachelor of Accountancy from the University of San Diego and is a CPA in California.
Publicly traded, clinical-stage biopharmaLB Pharmaceuticals, developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases, has appointed Joseph Miller as its CFO.
Miller brings more than two decades of experience leading financial strategy, operations, and enterprise transformation for publicly traded biotech and pharmaceutical companies. He joins as the company approaches pivotal clinical trial results and potential launch for two of its programs.
Miller most recently served as CFO of Aurinia Pharmaceuticals, and prior to that was CFO, principal executive officer, and corporate secretary of Avalo Therapeutics. He also held financial leadership positions with Sucampo Pharmaceuticals, QIAGEN, Eppendorf, and KPMG LLP. He holds a BS in accounting from Villanova University and is a CPA.
Lobe Sciences Ltd., a clinical-stage biopharmaceutical company advancing therapeutics for serious conditions with unmet medical needs, announced the appointment of David Kideckel, PhD, MBA, as its CFO.
Kideckel brings nearly two decades of experience across the life sciences, capital markets, and corporate advisory sectors. He has served in leadership roles at private investment banks, as well as with biopharma companies Rakovina Therapeutics, Johnson & Johnson Inc., and Alexion Pharmaceuticals.
Kideckel holds a PhD in neuroscience and statistics from the University of Toronto’s Institute of Medical Science and an MBA from the University of Toronto’s Rotman School of Management.
Publicly traded, biopharmaceutical companyOutlook Therapeutics, appointed Kevin Lundquist as its CFO. The company received FDA approval of its treatment for wet age-related macular degeneration in late July, and Lundquist joins as it builds the financial and operational infrastructure to support its planned U.S. commercial launch.
Lundquist brings more than 20 years of corporate finance and capital markets experience across the pharmaceutical, biotechnology, medical technology, and manufacturing industries for both public and private equity-backed companies, including commercial-stage businesses. He most recently served as CFO of CapsoVision and previously held leadership positions with Abzena Biologics, Revance Therapeutics, Genentech/Roche’s Drug Substance Biologics Operations, and Caterpillar’s Japan division. He holds an MBA in finance from Utah State University and a BS in accounting and finance from the University of Utah.
SCYNEXIS,a publicly traded, clinical-stage biotechnology company focused on rare diseases, announced Sanjay Subramanian, MBA, as its CFO. He replaces Ivor Macleod who announced his retirement, remaining through October 9 to support a smooth transition.
Subramanian brings more than 20 years of finance, capital markets, business development, and operational leadership experience across the biotechnology, pharmaceutical, and healthcare sectors. Most recently, he served as CFO and head of business development at Inozyme Pharma, leading the company’s acquisition by BioMarin Pharmaceutical. Previously, he served as CFO and head of corporate development at Ocugen and has held finance leadership roles with Aralez Pharmaceuticals, Bausch Health Companies, and General Motors. He holds an MBA from the MIT Sloan School of Management, master’s degrees from MIT and The Ohio State University, and a bachelor’s degree in mechanical engineering from the Indian Institute of Technology Madras.
Cardiometabolic therapeutics companySparrow Pharmaceuticalsappointed George Eldridge as its CFO. Eldridge brings more than two decades of biotechnology financial leadership to his role as the company grows its lead candidate program.
He most recently served as CFO of Abcuro, where he prepared the company for an initial public offering and prior to that as CFO of Aerovate Therapeutics, Inc., which he took public in 2021. He has also served in financial leadership roles with Lyndra Therapeutics, Sollis Therapeutics, Proteon, Targanta Therapeutics, Curis, and Boston Life Sciences. Eldridge began his career as an investment banker at Kidder Peabody & Co and holds a BA from Dartmouth College and an MBA from the University of Chicago, Booth School of Business.
WithVertex’s acquisition of Crinetics completed, the company announced that Jonathan Poole, current senior vice president of finance, will be appointed executive vice president (EVP), CFO, effective January 1, 2027. This move allows current EVP, CFO, and chief operating officer (COO) Charles Wagner to take on an expanded COO role overseeing the integration of Crinetics, effective immediately.
Poole has led Vertex’s global finance organization since March 2020. He previously served as CFO of Evelo Biosciences and Genocea Biosciences as well as senior vice president of finance at Shire Plc. Poole has an MBA from London University and a BS in biology from Durham University.
Publicly traded, clinical stage biopharmaceutical companyVyome Holdingsannounced the appointment of Jerry Leonard, CPA, MBA, as its CFO. Leonard is the founder and chief executive officer of ClearBridgeCFO, a financial leadership and transformation firm.
He brings over 25 years of experience to his role, including CFO positions at VSee Health, iDoc Virtual Telehealth Solutions, and VSee Lab. He also held financial leadership positions with Voya Financial, IBM and Colgate-Palmolive. Leonard began his career in public accounting at Arthur Andersen and PricewaterhouseCoopers. He is a CPA and holds an MBA from Emory University’s Goizueta Business School.
These announcements are from August 24 through September 21, 2026, as posted on BusinessWire, PRNewswire, Yahoo Finance, LinkedIn, SEC documents, or company postings. If your company has an executive appointment announcement related to finance and accounting, please forward to Brandy Fidler at [email protected].
Finance & Accounting for Bioscience
Tailored to the unique needs of bioscience companies, this CPE-accredited annual forum convenes the brightest financial and accounting minds from the nation’s leading trailblazers. Hear from industry experts on high impact topics such as strategies to scale the business, creating value, emerging risks and digital transformation.
